Randomized Phase III Trial Comparing Docetaxel Plus Epirubicin Versus Docetaxel Plus Capecitabine As First-line Treatment in Women with Advanced Breast Cancer
Overview
Authors
Affiliations
Background: The purpose of this study was to compare docetaxel plus epirubicin versus docetaxel plus capecitabine combinations as front-line treatment in women with advanced breast cancer (ABC).
Patients And Methods: Previously untreated patients with ABC were randomly assigned to receive docetaxel 75 mg/m(2) plus epirubicin 75 mg/m(2) (DE) on day 1 or docetaxel 75 mg/m(2) on day 1 plus capecitabine 950 mg/m(2) orally twice daily on days 1-14 (DC) in 21-day cycles. Previous anthracycline-based (neo)-adjuvant chemotherapy was allowed if completed >1 year before enrollment. The primary objective of the study was to compare time to disease progression (TTP).
Results: One hundred and thirty-six women were treated on each arm and median TTP was 10.6 versus 11.0 months (P = 0.7), for DE and DC, respectively. According to RECIST criteria we observed 15 (11%) versus 11 (8%) complete responses and 55 (40%) versus 61 (45%) partial responses (P = 0.8), with DE and DC, respectively. Severe toxicity included grade 3-4 neutropenia (57% versus 46%; P = 0.07), febrile neutropenia (11% versus 8%; P = 0.4), hand-foot syndrome (0% versus 4%; P = 0.02), grade 2-3 anemia (20% versus 7%; P = 0.001) and asthenia (12% versus 6%; P = 0.09) with DE and DC, respectively.
Conclusions: The DE and DC regimens have similar efficacy but different toxicity. Either regimen can be used as front-line treatment of ABC.
Wu J, Wang Z, Fu Y BMC Womens Health. 2025; 25(1):104.
PMID: 40055784 PMC: 11887160. DOI: 10.1186/s12905-025-03628-z.
Zeng H, Lv H, Zhang M, Niu L, Wang J, Sun H J Cancer Res Clin Oncol. 2025; 151(2):89.
PMID: 39979499 PMC: 11842397. DOI: 10.1007/s00432-025-06133-w.
Wang S, Deng L, Chen J, Li Y, Zhong Y, Wang Y J Cancer Res Clin Oncol. 2023; 149(19):17671-17682.
PMID: 37891407 DOI: 10.1007/s00432-023-05459-7.
Li D, Tao Z, Wang B, Wang L, Cao J, Hu X NPJ Breast Cancer. 2022; 8(1):110.
PMID: 36127351 PMC: 9489776. DOI: 10.1038/s41523-022-00462-6.
Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer.
Hoon S, Lau P, White A, Bulsara M, Banks P, Redfern A Cochrane Database Syst Rev. 2021; 5:CD011220.
PMID: 34037241 PMC: 8150746. DOI: 10.1002/14651858.CD011220.pub2.